Elanco Animal's Outlook Lags Street Expectations But Analyst Sees Time For Elanco's Commercial Investment To Payoff
Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a ...
Private Advisor Group LLC Acquires 8,848 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)
Private Advisor Group LLC increased its position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 6.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The ...
CSR Wire1d
Elanco Enters Agreement With Medgene To Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based ...
Elanco Animal Health 4Q Loss Narrows, Sales Decline
Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.
Elanco price target lowered to $15 from $16 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...
Elanco slips as forex headwinds weigh on outlook
Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.
Elanco Animal Health to Commercialize Vaccine for Dairy Cattle to Battle Bird Flu Outbreak
Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.
Elanco signs agreement with Medgene to commercialize avian influenza vaccine
Elanco (ELAN) has entered into an agreement with South Dakota-based Medgene to leverage the company’s innovative vaccine platform technology.